ライフサイエンスコーパス: preclinical

1 (ICH) induced by collagenase in mice using a preclinical 11.7 Tesla MRI system.

2 ominantly within certain parts of the DMN in preclinical AD and already then affect brain connectivit

3 al fluid (CSF) markers of neuronal injury in preclinical AD and risk of incident AD in the predictors

4 connectivity MRI (fcMRI) in individuals with preclinical AD have relied on associations with in vivo

5 at clarifying the nature of myelin damage in preclinical AD may be informative on the disease's cours

6 findings suggest that A2M is associated with preclinical AD, reflects early neuronal injury in the di

7 by a hypoconnectivity phase in the course of preclinical AD.SIGNIFICANCE STATEMENT This article offer

8 t risk for cognitive decline associated with preclinical AD.SIGNIFICANCE STATEMENT Understanding how

9 Achieving the goals of the AGI also requires preclinical advances, new imaging techniques, and optimi

10 efficient enantioselective synthesis of the preclinical agent OPC 51803.

11 As a result, much preclinical alcohol research aims to identify relevant C

12 Outcomes included scores on the Preclinical Alzheimer Cognitive Composite (PACC; a sum o

13 Motor slowing appears in preclinical Alzheimer disease (AD), progresses with AD p

14 als who would be categorised as stage 2 or 3 preclinical Alzheimer's disease (A+T+N-, A+T-N+, and A+T

15 etween amyloid and fcMRI in individuals with preclinical Alzheimer's disease.

16 ion was within +/-17%, permitting its use in preclinical and clinical applications.

17 bility to provide relevant information under preclinical and clinical circumstances, their in vivo sa

18 on mAbs and antibody-related theranostics in preclinical and clinical oncologic settings.

19 ic activity and is a promising candidate for preclinical and clinical PET imaging of hNIS expression

20 imaging) has become increasingly deployed in preclinical and clinical research due to its rapid and a

21 Substantial preclinical and clinical research into chronic graft-ver

22 Effects of CD39 and CD73 inhibition in preclinical and clinical studies are discussed.

23 Evidence from preclinical and clinical studies implicate dopamine hypo

24 A growing number of preclinical and clinical studies support the inflammator

25 However, the outcomes from preclinical and clinical studies vary, highlighting a ne

26 toward a well-planned, step-wise sequence of preclinical and clinical studies, to determine whether t

27 sed, as are examples of their application in preclinical and clinical studies.

28 ers will engender novel hypotheses in future preclinical and clinical studies.

29 PCs and is being targeted therapeutically in preclinical and early clinical studies.

30 Preclinical and experimental studies show that PDE5 inhi

31 Therefore, accumulating preclinical and preliminary clinical evidence indicates

32 Preclinical and preliminary clinical evidence indicates

33 toxin activity provide a survival benefit in preclinical animal models and prevent recurrent infectio

34 s) improves recovery from tissue ischemia in preclinical animal models by still unknown mechanisms.

35 f IgG, and reduces circulating IgG levels in preclinical animal models.

36 this article, evidence from recent human and preclinical animal studies is reviewed, indicating that

37 to supplant traditional 2D cell cultures and preclinical animal studies that have historically been t

38 Preclinical animal testing often fails to predict advers

39 ntification and evaluation myelin deficit in preclinical animals and potentially in para-clinical hum

40 Buparlisib, a pan-PI3K inhibitor, has shown preclinical antitumour activity and objective responses

41 t study was to translate these findings into preclinical applications using an RNA interference (RNAi

42 of this promising cell type in clinical and preclinical applications.

43 Therefore, a rapid preclinical approach is needed to evaluate whether simul

44 sured in adolescence independently predicted preclinical atherosclerosis in young adulthood.

45 Thus, the translational potential of preclinical BE studies is particularly strong.

46 n of delamanid analogue DNDI-VL-2098 as a VL preclinical candidate, this structurally related 7-subst

47 The lead compounds are promising as preclinical candidates for the treatment of HCV infectio

48 The leading compounds represent viable preclinical candidates for the treatment of type 2 diabe

49 rdiac cells may be feasible for large animal preclinical cardiac regeneration paradigms.

50 Because of its favorable preclinical characteristics, (18)F-GP1 is currently bein

51 titumor immune responses and report here the preclinical characterization and toxicity assessment of

52 Comprehensive preclinical characterization of ABBV-075 demonstrated br

53 Here we report the synthesis and preclinical characterization of the first inhibitor of h

54 to their associations with cancer drugs and preclinical compounds.

55 Preclinical data demonstrate increased CD30 expression o

56 Preclinical data suggest that combining antivirals might

57 Consistent with our preclinical data, we observed Slc6a15 mRNA reduction in

58 mones peptide YY and ghrelin is supported by preclinical data.

59 A preclinical development candidate was selected for which

60 RNA mimics and miRNA inhibitors currently in preclinical development have shown promise as novel ther

61 an additional 40-plus candidate vaccines in preclinical development.

62 with the potential to be moved to the early preclinical development.

63 topes remains a significant challenge in mAb preclinical development.

64 Second, preclinical discoveries are at a point that they can be

65 use model disease progression and evaluating preclinical disease-modifying treatment response.

66 -source literature-based database focused on preclinical drug discovery.

67 maging technologies are increasingly used in preclinical drug research for the pharmacokinetic analys

68 d provides an alternative to PET analysis in preclinical drug research.

69 This model will prove useful for preclinical drug studies and for elucidating the develop

70 Current preclinical drug testing does not predict some forms of

71 ifferentiated cells for disease modeling and preclinical drug testing.

72 nd represents a revolutionary tool to assess preclinical drug-induced arrhythmogenicity.

73 ive 5-HT2C ligands and herein describe their preclinical effectiveness for treating schizophrenia-lik

74 We investigated the preclinical effects of AZD1775 in the context of KRAS/LK

75 idate, 55 (FXIa Ki = 0.7 nM), with excellent preclinical efficacy in thrombosis models and aqueous so

76 Preclinical efficacy in triple combination and high sele

77 Promising preclinical efficacy results from both in-vitro and in-v

78 bioavailable and brain penetrant with robust preclinical efficacy.

79 Furthermore, translation of therapies from preclinical efforts capable of delaying or halting beta-

80 lopyridines and that KDU731 warrants further preclinical evaluation as a drug candidate for the treat

81 We report the synthesis and preclinical evaluation of a (11)C-labeled probe to targe

82 We describe the development and preclinical evaluation of an attenuated recombinant huma

83 Here, we describe the development and preclinical evaluation of RYM1 in comparison with RP805,

84 These preclinical evaluation results demonstrate the clinical

85 These preclinical evaluations show a high propensity of 4-(11)

86 This work provides initial preclinical evidence for targeting RPS19 for anticancer

87 cokinetic agents has demonstrated convincing preclinical evidence of clinical potential for drug over

88 Here we provide preclinical evidence of the therapeutic potential of hig

89 Here, we report preclinical evidence suggesting weight maintenance throu

90 Our results provide critical preclinical evidence supporting treatment of epilepsy an

91 We provide preclinical evidence that combining conventional magneti

92 st focus on interventions/agents with robust preclinical evidence, have solid phase II dosing and tim

93 treatments or experimental manipulations in preclinical experimental biomedicine almost exclusively

94 are very small, as is currently prevalent in preclinical experimental biomedicine.

95 ntibodies has produced impressive results in preclinical experiments and in clinical trials conducted

96 the antitumor activity of MOv18 IgE in these preclinical experiments can be replicated in patients.

97 Early preclinical experiments using the non-obese diabetic (NO

98 n are scarce, and it is unclear whether such preclinical findings are relevant for the pediatric sett

99 These preclinical findings may provide insight into why patien

100 to receptor tyrosine kinase inhibition in a preclinical glioblastoma model, which may have important

101 muscle tissues based on a rabbit model and a preclinical HIFU system.

102 d chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) models at

103 Preclinical identification of fast-onset antidepressants

104 The different preclinical imaging modalities available differ intrinsi

105 This article describes the preclinical in vitro and in vivo characterization of 3 n

106 n concerns to deliver the desired balance of preclinical in vitro properties.

107 sease models is particularly useful whenever preclinical in vivo cell tracking is of interest.

108 Our previous preclinical in vivo experiments demonstrated that only c

109 best knowledge of the authors, there are no preclinical in vivo studies in implant dentistry that ha

110 er burden of cardiovascular risk factors and preclinical indices of CVD, these associations are mainl

111 Here we determine, via preclinical infection models of Brugia malayi or Onchoce

112 id-sparing antinociceptive effects in myriad preclinical inflammatory and neuropathic pain models.

113 is clinical scenario has been studied at the preclinical level using different animal models in which

114 Preclinical literature suggests latent effects of early

115 These findings suggest that research on preclinical markers for Alzheimer disease should take th

116 Lower BMI in preclinical MCs was significantly associated with less y

117 Our results establish a preclinical mechanistic rationale for the clinical devel

118 ents.Significance: These results establish a preclinical mechanistic rationale for the clinical devel

119 Overall, our results offered a preclinical mechanistic rationale for the use of PARP an

120 In a preclinical model developed in our laboratory, rats exhi

121 To establish a preclinical model for therapeutic inhibition of putative

122 d by the lack of a physiologically relevant, preclinical model of allogeneic HSCT.

123 ted sodium channel Nav1.7 are increased in a preclinical model of chemotherapy-induced peripheral neu

124 gical inhibitors of MRTF/SRF signalling in a preclinical model of fibrosis.

125 iral vector carrying I-1c (BNP116.I-1c) in a preclinical model of nonischemic HF, and to assess thoro

126 tion, and promising therapeutic profile in a preclinical model of prostate cancer.

127 We demonstrate that our preclinical model recapitulates the cardio-respiratory d

128 23414 demonstrates efficacy against EAC in a preclinical model, establishing the rationale for clinic

129 namics readouts to monitor their efficacy in preclinical models and in HD patients.

130 modifiers alter disease progression in both preclinical models and subjects with Duchenne muscular d

131 digm for designing more flexible and dynamic preclinical models for these as well as other acute leuk

132 autoimmune diseases and numerous studies in preclinical models highlights the potential of regulator

133 In addressing this issue, preclinical models may be limited by the inability to ac

134 f current standard-of-care chemotherapies in preclinical models of advanced pancreatic and ovarian ca

135 tic therapy approaches have been explored in preclinical models of AF, and offer potential as a treat

136 fects of cortistatin in two well-established preclinical models of atherosclerosis, and the molecular

137 y in vitro and in vivo, including in various preclinical models of CDI.

138 Preclinical models of Chagas disease have demonstrated t

139 er disease states and are neuroprotective in preclinical models of critical illness.

140 the therapeutic potential of ELNs induction, preclinical models of ELNs are needed for interrogation

141 tionale for future studies targeting Ncad in preclinical models of EOC metastasis.

142 In preclinical models of experimental metastasis, ectopic e

143 inhibited disease progression in aggressive preclinical models of human cancers and induced cell kil

144 Studies in preclinical models of influenza virus infections have sh

145 iopsies from patients with active IBD and in preclinical models of intestinal inflammation.

146 strategy towards the development of scalable preclinical models of liver stage malaria infection for

147 stasis-targeting peptidomimetic (BMTP-11) in preclinical models of primary intratibial osteosarcomas,

148 Based on synergy in preclinical models of PTCL, we initiated a phase 1 study

149 ptotic function of Bcl-2 is highly active in preclinical models of refractory acute myeloid leukemia

150 o, allowing creation of genetically accurate preclinical models of these disorders.

151 Furthermore, studies in preclinical models suggest that decreasing IL-6 activity

152 -modifying therapies for CMML, nor are there preclinical models that fully recapitulate the unique fe

153 of death in the developed world, yet facile preclinical models that mimic the natural stages of CRC

154 ective radiosensitizing agents in a range of preclinical models using broad field sources of various

155 ogical tools to study anti-ZIKV responses in preclinical models, particularly T cell responses, remai

156 ted osteolysis and metastatic progression in preclinical models, suggesting a new treatment opportuni

157 Based on the phenotypes of our preclinical models, the FLCN H255Y mutant protein has lo

158 nce to BET inhibitors has been documented in preclinical models, the molecular mechanisms underlying

159 istance, people have successfully tested, in preclinical models, treatments targeting specific resist

160 h better than either single agent in several preclinical models.

161 therapy with rituximab enhanced activity in preclinical models.

162 ave been shown to be safe and immunogenic in preclinical models.

163 es treatment from several weeks to 7 days in preclinical models.

164 both in vitro assays and in vivo orthotopic preclinical models.

165 iomarker than GlcCer for neuronopathic GD in preclinical models.

166 In a preclinical mouse model of breast cancer, CCL21-mediated

167 Using a preclinical mouse model, we found that small ruptures of

168 nerative medicine and are frequently used in preclinical mouse models for both mechanistic studies an

169 Here we have combined preclinical mouse models of liver cancer and genetic stu

170 l expansion in CD patients, human cells, and preclinical mouse models.

171 ds of healthy donors and are being tested in preclinical mouse models.

172 ek for 10 weeks and were imaged with a 7.0-T preclinical MR imaging unit at baseline and 1 week after

173 Preclinical multiparametric diagnostics could help disco

174 PPARgamma is therapeutically effective in a preclinical murine model of steatosis-associated liver c

175 Alzheimer Network (DIAN) study including 120 preclinical mutation carriers (MCs) and 110 asymptomatic

176 repositioning candidates, many supported by preclinical or clinical evidence.

177 ation conditions) and in vivo experiments in preclinical PAD models (unilateral femoral artery ligati

178 ble risk factor or therapeutic target in the preclinical phases of AD.

179 biomarkers needed to detect nonsymptomatic, preclinical phases of the disease.

180 Finally, in the preclinical pig kidney transplant model, intravenous inj

181 The design strategies and results from preclinical PK and clinical human microdose PK data are

182 rticular promise for the characterization of preclinical populations; target populations for disease

183 ozen antifibrotic agents possessing exciting preclinical potential in the armory, it seems certain th

184 On the basis of its favorable and unique preclinical profile, compound 60 (PXT002331, now foliglu

185 Together, these new findings provide a preclinical proof of concept defining C1572 as a promisi

186 Our studies offer a preclinical proof of concept for a strategy of cotargeti

187 of poor prognosis in TNBC, and they offer a preclinical proof of concept for combining CDK7 and BCL-

188 Overall, our results offer preclinical proof of concept for H3B-6527 as a candidate

189 Our findings offer a preclinical proof of concept for immunotherapeutic targe

190 at TNBC.Significance: These findings offer a preclinical proof of concept for immunotherapeutic targe

191 Our findings offer a preclinical proof of concept for small-molecule therapie

192 Together, our results offer a preclinical proof of concept for the low-dose use of iso

193 Collectively, our results offer a preclinical proof of concept for the use of anti-Jagged1

194 k TPC to cancer cell migration and provide a preclinical proof of concept for their candidacy as targ

195 Our findings provide a preclinical proof of concept supporting the initiation o

196 As a preclinical proof of concept, specific tumor uptake, pha

197 rom animal models and human material provide preclinical proof-of-principle that validates uPA as a n

198 ents of non-heme cellular iron revealed that preclinical prostate tumor models could be differentiate

199 The excellent concordance between the preclinical (rat, NHP) and human studies with PF-0495824

200 rate two aggressive CLL models and provide a preclinical rational for the use of PARP inhibitors in A

201 Overall, our findings provide a preclinical rationale for the clinical development of MA

202 olorectal cancer progression, establishing a preclinical rationale to target this activation loop to

203 olorectal cancer progression, establishing a preclinical rationale to target this activation loop.

204 These findings provide key clinical and preclinical relevance to the conformational immunoassay,

205 e sensitivity and precision of CT applied to preclinical research (micro-CT).

206 Preclinical research has shown that the gastrointestinal

207 These models offer a platform to enable new preclinical research into mechanisms and prevention of e

208 ati and Todd Rasmussen summarize progress in preclinical research on cellular therapeutics for trauma

209 Preclinical research shows that compounds acting at alph

210 Collectively, preclinical results demonstrate beneficial effects of DM

211 Preclinical results in a variety of induced and spontane

212 Overall, these preclinical results provide an empirical foundation supp

213 These preclinical results support the importance of androgens

214 ressant actions in depressed patients and in preclinical rodent models.

215 Results from preclinical rodent studies during the last 20 years impl

216 e and absence of oil-in-water adjuvant) in a preclinical RSV susceptible cotton rat challenge model c

217 st MDR A. baumannii infections and promising preclinical safety demonstrate its potential to address

218 hanism of action is a critical component for preclinical safety evaluation, and we demonstrate here t

219 ve breast cancer patients, and predictive of preclinical sensitivity to this drug combination.

220 of current and new protocols is rare even in preclinical settings.

221 to investigate the capabilities of combined preclinical single photon emission computed tomography (

222 aim of this study was to advance an existing preclinical single-port system for clinical application

223 of the scaffold, pharmacokinetic studies in preclinical species, and the in vivo efficacy of THIQ 40

224 mpared to 29 and showed good tolerability in preclinical species.

225 ication, for identifying participants at the preclinical stage of AD who may be at risk for cognitive

226 mitochondrial disorders are now at a mature preclinical stage.

227 ly increased over the past decade, except in preclinical stroke research, which has uniquely demonstr

228 HS mouse models and provide a foundation for preclinical studies and a rationale for testing whether

229 In addition, preclinical studies and clinical trials demonstrate the

230 has shown promise as a cancer therapeutic in preclinical studies and early-phase clinical trials.

231 ine is described, and key findings from both preclinical studies and the GLP-2 clinical development p

232 In preclinical studies CD276 ADCs armed with a conventional

233 cular perturbations of hyperammonemia; these preclinical studies complement previous studies on ammon

234 Previous preclinical studies demonstrate that active and passive

235 Preclinical studies demonstrated pegvorhyaluronidase alf

236 Preclinical studies have established its role in maintai

237 Preclinical studies have found radiotherapy enhances ant

238 Although preclinical studies have in part described this systemic

239 Preclinical studies have mostly focused on modeling righ

240 Preclinical studies have shown convincingly in rodent mo

241 Recent preclinical studies have suggested that it also inhibits

242 Clinical and preclinical studies indicate that early postnatal exposu

243 In particular, preclinical studies indicate that females may be more se

244 Preclinical studies indicate that most antidepressants m

245 d reduces alveolar edema and inflammation in preclinical studies of lung injury, but its therapeutic

246 types that may serve as outcome measures for preclinical studies of PTHS treatments.

247 Preclinical studies show that arginine deprivation is sy

248 Preclinical studies showed significant disease regressio

249 sed on our findings, and coupled with recent preclinical studies showing the importance of multiple n

250 The results of preclinical studies suggest that anesthetic drugs admini

251 Preclinical studies suggest that extracellular signal-re

252 n the translation of mechanisms derived from preclinical studies to complementary findings in clinica

253 1 antagonist) was compared with SB-705498 in preclinical studies to establish whether an improved eff

254 Preclinical studies using a variety of approaches to red

255 Preclinical studies using genetically engineered mouse m

256 ous than maximum tolerated dose treatment in preclinical studies, and is currently being tested in th

257 On the basis of several preclinical studies, cell-based therapy has emerged as a

258 In preclinical studies, combination therapy with compound 7

259 Through review of preclinical studies, retrospective clinical studies, and

260 r pharmacogenomics discovery is conducted in preclinical studies, typically using cell lines and mous

261 In preclinical studies, venetoclax enhanced bortezomib acti

262 ors have shown potential for gene therapy in preclinical studies.

263 ces and then was utilized in fundamental and preclinical studies.

264 l biodistribution, tumor homing, and fate in preclinical studies.

265 led phase 2 and 3 trials, and also pertinent preclinical studies.

266 derived cells have been investigated in many preclinical studies.

267 quality is a main cause of discrepancies in preclinical studies.

268 t enough (IC50 approximately 53 nM) to enter preclinical studies.

269 LINGO-1) has shown remyelinating activity in preclinical studies.

270 and permanent noise-induced hearing loss in preclinical studies.

271 gineered livers for organ transplantation in preclinical studies.

272 g delivery highlighting their performance in preclinical studies.

273 This preclinical study demonstrates the potential of repurpos

274 linical practice.Significance: This detailed preclinical study of the long-term effects of widely use

275 The purpose of this preclinical study was to further explore the use of NeoB

276 Although the subject of intense preclinical study, predictive biomarkers for response an

277 In this preclinical study, we first demonstrate that a mouse mod

278 , our study provides a general framework for preclinical target validation.

279 ritical property for chemical probes used in preclinical target validation.

280 ng of intraplaque hemorrhage, establishing a preclinical technology to assess and monitor plaque inst

281 in patient tumors ex vivo, thereby enabling preclinical testing of novel drugs and helping stratify

282 humanized mouse model may thus be useful for preclinical testing of novel human NK cell-targeted and

283 practice is hindered by the lack of thorough preclinical testing using representative animal models a

284 ools available to researchers for systematic preclinical testing.

285 man skull porcine model was designed for the preclinical testing.

286 eliable biomarkers are imperative before any preclinical therapeutics can find clinical translation.

287 Microdosing regulations specify a reduced preclinical toxicology-assessment package in order to sh

288 Advances in preclinical translational science point to potential tar

289 ft-versus-host disease (GvHD) in both murine preclinical transplant models and in human clinical tria

290 Anti-ErbB therapies were efficient only in preclinical trials and have suggested the existence of r

291 We performed preclinical trials investigating primary murine acute my

292 have displayed favorable activity in several preclinical tumor models, often in the molecular context

293 GITR exert potent therapeutic activities in preclinical tumor models.

294 ributed to excess glucose consumption by the preclinical tumour, we used data from the Apolipoprotein

295 e application of an insect-specific virus in preclinical vaccine development and highlights the poten

296 Promising data from preclinical vaccine studies in mice and monkeys suggest

297 ed experiments from the paper "Discovery and Preclinical Validation of Drug Indications Using Compend

298 g class provide a bench-to-bedside review on preclinical validation of IDO1 as a cancer therapeutic t

299 Purpose Our preclinical work identified depletion of ATR as a top ca

300 c countermeasures developed through years of preclinical work, including the first clinical trials fo